Program Schedule

Modeling of nasopharyngeal acquisition as a function of anti-capsular serum antibody concentrations and of ethnicity after vaccination with pneumococcal conjugate vaccines (PCVs)

Session: Poster Abstract Session: Vaccines: Pneumococcal
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • PIP14186.3026.pdf (1.0 MB)
  • Background: A large 13- and 7-valent PCV study in Israel provided sufficient nasopharyngeal (NP-) acquisition and immunogenicity data for the 7 common serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) and PCV7 cross-reacting serotype 6A (which is in PCV13) to further investigate the reported correlation between NP-acquisition and serum IgG levels, and the impact of ethnicity.

    Methods: Anticapsular IgG concentrations measured one month after 3 PCV7/PCV13 doses (age = 7 months); and NP-acquisition collected at ages 7, 12, 13, 18 and 24 months enabled serotype specific analyses of 14101530 subjects. A logistic regression model assessed the rate of new acquisitions as a function of the logarithm of IgG concentrations, and was then adjusted by ethnicity.

    New NP-acquisition rates decreased as IgG concentrations increased for all studied serotypes (p<0.001 for 6A, 14, 23F; p=0.010 for 6B; p=0.089 for 19F; Figure 1). There were significant differences in the model between Bedouin and Jewish populations for all serotypes (covariate p-value, ≤0.007) except for serotype 4, where acquisition was low (9/1530). Despite higher acquisition rates in Bedouin children than in Jewish children, serotype-specific immune responses were similar across ethnic groups. Decrease in rates of NP-acquisition by increasing IgG concentrations within each ethnic group, seemed similar across the groups for most serotypes (Figure 2).


    PIP14186 2013_Fig1.tiff


    PIP14186 2013_Fig2.tif


    Conclusion: NP-acquisition decreased with increasing anti-capsular serum IgG for all common serotypes and serotype 6A. Despite different NP-acquisition rates observed between the ethnic groups, the dynamics of NP-acquisition reduction by increasing IgG concentrations were similar in the majority of serotypes studied, and seemed similar across ethnic groups.


    Ron Dagan, MD1, Christine Juergens, MD2, James Trammel3, Scott D. Patterson, PhD4, David Greenberg, MD5, Noga Givon-Lavi, PhD6, Nurith Porat7, William C. Gruber, MD8 and Daniel A. Scott, MD8, (1)Ben-Gurion University and Soroka Univ Med Ctr, Beer-Sheva, Israel, (2)Pfizer Pharma GmbH, Berlin, Germany, (3)inVentiv Health Clinical, Princeton, NJ, (4)Pfizer Vaccine Clinical Research, Collegeville, PA, (5)Ben-Gurion Univ of the Negev and Soroka Univ Med Ctr, Beer-Sheva, Israel, (6)Pediatric Infectious Disease Unit, Ben-Gurion Univ of the Negev and Soroka Univ Med Ctr, Beer-Sheva, Israel, (7)Ben Gurion Univ and Soroka Univ Med Ctr, Beer Sheva, Israel, (8)Pfizer Vaccine Research, Pearl River, NY


    R. Dagan, Pfizer: Consultant and Speaker's Bureau, Grant recipient
    MSD: Consultant, Grant recipient
    GSK: Consultant and Speaker's Bureau, Speaker honorarium

    C. Juergens, Pfizer: Employee and Shareholder, Salary

    J. Trammel, inVentiv Health Clinical: employee of CRO contracted by Pfizer to perform the analyses for this study, Salary

    S. D. Patterson, Pfizer Vaccines Clinical Research: Employee, Salary

    D. Greenberg, None

    N. Givon-Lavi, None

    N. Porat, None

    W. C. Gruber, Pfizer: Employee and Shareholder, Salary

    D. A. Scott, Pfizer: Employee and Shareholder, Salary

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek